KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent Deferred Tax AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Total Debt (2016 - 2025)

Pfizer (PFE) has disclosed Total Debt for 17 consecutive years, with $64.8 billion as the latest value for Q4 2025.

  • Quarterly Total Debt rose 1.33% to $64.8 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $64.8 billion through Dec 2025, up 1.33% year-over-year, with the annual reading at $64.8 billion for FY2025, 1.33% up from the prior year.
  • Total Debt for Q4 2025 was $64.8 billion at Pfizer, up from $61.7 billion in the prior quarter.
  • The five-year high for Total Debt was $71.9 billion in Q4 2023, with the low at $35.8 billion in Q4 2022.
  • Average Total Debt over 5 years is $53.2 billion, with a median of $61.8 billion recorded in 2025.
  • The sharpest move saw Total Debt tumbled 38.31% in 2021, then soared 100.64% in 2023.
  • Over 5 years, Total Debt stood at $38.4 billion in 2021, then dropped by 6.78% to $35.8 billion in 2022, then skyrocketed by 100.64% to $71.9 billion in 2023, then decreased by 11.05% to $63.9 billion in 2024, then grew by 1.33% to $64.8 billion in 2025.
  • According to Business Quant data, Total Debt over the past three periods came in at $64.8 billion, $61.7 billion, and $61.8 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.